Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Dezember 2020 07:00 ET | Quelle: Prevail Therapeutics

Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
30. November 2020 07:00 ET | Quelle: Prevail Therapeutics

Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
18. November 2020 19:02 ET | Quelle: Prevail Therapeutics

Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
13. November 2020 07:00 ET | Quelle: Prevail Therapeutics

Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE Trial of PR001 for Type 2 Gaucher Disease and Phase 1/2 PROCLAIM Trial of...
10. November 2020 07:00 ET | Quelle: Prevail Therapeutics

Prevail Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
02. November 2020 07:00 ET | Quelle: Prevail Therapeutics

Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
27. Oktober 2020 07:00 ET | Quelle: Prevail Therapeutics

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease

NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
25. September 2020 17:21 ET | Quelle: Prevail Therapeutics

Prevail Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
18. September 2020 15:04 ET | Quelle: Prevail Therapeutics

Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
10. September 2020 07:00 ET | Quelle: Prevail Therapeutics

Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of Directors

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

Nächste Seite